A citation-based method for searching scientific literature

Wim A Wuyts, Carlo Agostini, Katerina M Antoniou, Demosthenes Bouros, Rachel C Chambers, Vincent Cottin, Jim J Egan, Bart N Lambrecht, Rik Lories, Helen Parfrey, Antje Prasse, Carlos Robalo-Cordeiro, Eric Verbeken, Johny A Verschakelen, Athol U Wells, Geert M Verleden. Eur Respir J 2013
Times Cited: 155







List of co-cited articles
663 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Ganesh Raghu, Harold R Collard, Jim J Egan, Fernando J Martinez, Juergen Behr, Kevin K Brown, Thomas V Colby, Jean-François Cordier, Kevin R Flaherty, Joseph A Lasky,[...]. Am J Respir Crit Care Med 2011
25

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue,[...]. N Engl J Med 2014
18

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu, Martine Remy-Jardin, Jeffrey L Myers, Luca Richeldi, Christopher J Ryerson, David J Lederer, Juergen Behr, Vincent Cottin, Sonye K Danoff, Ferran Morell,[...]. Am J Respir Crit Care Med 2018
18

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster,[...]. N Engl J Med 2014
16

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
Ganesh Raghu, Bram Rochwerg, Yuan Zhang, Carlos A Cuello Garcia, Arata Azuma, Juergen Behr, Jan L Brozek, Harold R Collard, William Cunningham, Sakae Homma,[...]. Am J Respir Crit Care Med 2015
985
14

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Ganesh Raghu, Kevin J Anstrom, Talmadge E King, Joseph A Lasky, Fernando J Martinez. N Engl J Med 2012
882
13

Idiopathic pulmonary fibrosis.
Luca Richeldi, Harold R Collard, Mark G Jones. Lancet 2017
499
13

Idiopathic pulmonary fibrosis: pathogenesis and management.
Giacomo Sgalla, Bruno Iovene, Mariarosaria Calvello, Margherita Ori, Francesco Varone, Luca Richeldi. Respir Res 2018
139
12

Idiopathic pulmonary fibrosis.
Talmadge E King, Annie Pardo, Moisés Selman. Lancet 2011
10

Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
Brett Ley, Harold R Collard, Talmadge E King. Am J Respir Crit Care Med 2011
876
10

Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.
John Hutchinson, Andrew Fogarty, Richard Hubbard, Tricia McKeever. Eur Respir J 2015
343
10

A common MUC5B promoter polymorphism and pulmonary fibrosis.
Max A Seibold, Anastasia L Wise, Marcy C Speer, Mark P Steele, Kevin K Brown, James E Loyd, Tasha E Fingerlin, Weiming Zhang, Gunnar Gudmundsson, Steve D Groshong,[...]. N Engl J Med 2011
617
9

An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
William D Travis, Ulrich Costabel, David M Hansell, Talmadge E King, David A Lynch, Andrew G Nicholson, Christopher J Ryerson, Jay H Ryu, Moisés Selman, Athol U Wells,[...]. Am J Respir Crit Care Med 2013
9

TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease.
Brigham C Willis, Zea Borok. Am J Physiol Lung Cell Mol Physiol 2007
729
9

Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions.
Veronica Della Latta, A Cecchettini, S Del Ry, M A Morales. Pharmacol Res 2015
167
9

Cellular interactions in the pathogenesis of interstitial lung diseases.
Gianluca Bagnato, Sergio Harari. Eur Respir Rev 2015
138
8

Pathogenesis of idiopathic pulmonary fibrosis.
Paul J Wolters, Harold R Collard, Kirk D Jones. Annu Rev Pathol 2014
374
8


Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study.
Imre Noth, Yingze Zhang, Shwu-Fan Ma, Carlos Flores, Mathew Barber, Yong Huang, Steven M Broderick, Michael S Wade, Pirro Hysi, Joseph Scuirba,[...]. Lancet Respir Med 2013
309
7

Oxidative stress and pulmonary fibrosis.
Paul Cheresh, Seok-Jo Kim, Sandhya Tulasiram, David W Kamp. Biochim Biophys Acta 2013
220
7


Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11.
Ganesh Raghu, Shih-Yin Chen, Wei-Shi Yeh, Brad Maroni, Qian Li, Yuan-Chi Lee, Harold R Collard. Lancet Respir Med 2014
318
7


The impact of TGF-β on lung fibrosis: from targeting to biomarkers.
Isis E Fernandez, Oliver Eickelberg. Proc Am Thorac Soc 2012
352
7

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
Harold R Collard, Christopher J Ryerson, Tamera J Corte, Gisli Jenkins, Yasuhiro Kondoh, David J Lederer, Joyce S Lee, Toby M Maher, Athol U Wells, Katerina M Antoniou,[...]. Am J Respir Crit Care Med 2016
539
7

Immune Mechanisms in Pulmonary Fibrosis.
Saeed Kolahian, Isis E Fernandez, Oliver Eickelberg, Dominik Hartl. Am J Respir Cell Mol Biol 2016
104
7


Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span.
Alexander V Misharin, Luisa Morales-Nebreda, Paul A Reyfman, Carla M Cuda, James M Walter, Alexandra C McQuattie-Pimentel, Ching-I Chen, Kishore R Anekalla, Nikita Joshi, Kinola J N Williams,[...]. J Exp Med 2017
372
7

Idiopathic Pulmonary Fibrosis.
David J Lederer, Fernando J Martinez. N Engl J Med 2018
451
7

Inflammation and immunity in IPF pathogenesis and treatment.
P Heukels, C C Moor, J H von der Thüsen, M S Wijsenbeek, M Kool. Respir Med 2019
77
9

Pulmonary fibrosis: patterns and perpetrators.
Paul W Noble, Christina E Barkauskas, Dianhua Jiang. J Clin Invest 2012
277
6

Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix.
Kevin K Kim, Matthias C Kugler, Paul J Wolters, Liliane Robillard, Michael G Galvez, Alexis N Brumwell, Dean Sheppard, Harold A Chapman. Proc Natl Acad Sci U S A 2006
895
6

Animal models of fibrotic lung disease.
Bethany B Moore, William E Lawson, Tim D Oury, Thomas H Sisson, Krishnan Raghavendran, Cory M Hogaboam. Am J Respir Cell Mol Biol 2013
218
6


Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis.
Tasha E Fingerlin, Elissa Murphy, Weiming Zhang, Anna L Peljto, Kevin K Brown, Mark P Steele, James E Loyd, Gregory P Cosgrove, David Lynch, Steve Groshong,[...]. Nat Genet 2013
422
6


The epithelium in idiopathic pulmonary fibrosis: breaking the barrier.
Ana Camelo, Rebecca Dunmore, Matthew A Sleeman, Deborah L Clarke. Front Pharmacol 2014
127
5

Mechanisms of fibrosis: therapeutic translation for fibrotic disease.
Thomas A Wynn, Thirumalai R Ramalingam. Nat Med 2012
5


Molecular mechanisms of epithelial-mesenchymal transition.
Samy Lamouille, Jian Xu, Rik Derynck. Nat Rev Mol Cell Biol 2014
5

Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature.
Luba Nalysnyk, Javier Cid-Ruzafa, Philip Rotella, Dirk Esser. Eur Respir Rev 2012
276
5

Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function.
Guoying Yu, Argyris Tzouvelekis, Rong Wang, Jose D Herazo-Maya, Gabriel H Ibarra, Anup Srivastava, Joao Pedro Werneck de Castro, Giuseppe DeIuliis, Farida Ahangari, Tony Woolard,[...]. Nat Med 2018
138
5

Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.
Roland M du Bois, Derek Weycker, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Alex Kartashov, Talmadge E King, Lisa Lancaster, Paul W Noble, Steven A Sahn,[...]. Am J Respir Crit Care Med 2011
285
5

Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.
C J Zappala, P I Latsi, A G Nicholson, T V Colby, D Cramer, E A Renzoni, D M Hansell, R M du Bois, A U Wells. Eur Respir J 2010
217
5

The pathogenesis of idiopathic pulmonary fibrosis.
William R Coward, Gauri Saini, Gisli Jenkins. Ther Adv Respir Dis 2010
179
5

Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis.
Camille Taillé, Sabine Grootenboer-Mignot, Céline Boursier, Laurence Michel, Marie-Pierre Debray, Jérôme Fagart, Lorena Barrientos, Arnaud Mailleux, Natacha Cigna, Florence Tubach,[...]. Am J Respir Crit Care Med 2011
71
7

Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis.
Harikrishna Tanjore, Xiaochuan C Xu, Vasiliy V Polosukhin, Amber L Degryse, Bo Li, Wei Han, Taylor P Sherrill, David Plieth, Eric G Neilson, Timothy S Blackwell,[...]. Am J Respir Crit Care Med 2009
296
5

Pulmonary fibrosis: pathogenesis, etiology and regulation.
M S Wilson, T A Wynn. Mucosal Immunol 2009
429
5

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Marilyn K Glassberg, David Kardatzke, Talmadge E King, Lisa Lancaster, Steven A Sahn, Javier Szwarcberg,[...]. Lancet 2011
5

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Lutz Wollin, Eva Wex, Alexander Pautsch, Gisela Schnapp, Katrin E Hostettler, Susanne Stowasser, Martin Kolb. Eur Respir J 2015
348
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.